IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors

NCT03665129 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

73

Enrollment

INDUSTRY

Sponsor class

Stopped early termination

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL: IPH5401 and Durvalumab

Sponsor

Innate Pharma

Collaborators

[object Object]